Phase i trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma

Neuro-Oncology

Volumn 10, Issue 3, 2008, Pages 341-347

  Haas Kogan, Daphne A ^a,g   Banerjee, Anuradha ^a,d   Kocak, Mehmet ^b   Prados, Michael D ^a   Geyer, J Russell ^c   Fouladi, Maryam ^d   McKnight, Tracy ^a   Poussaint, Tina Young ^e   Broniscer, Alberto ^a,d   Blaney, Susan M ^f   Boyett, James M ^b   Kun, Larry E ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Operations and Biostatistics Center for the Pediatric Brain Tumor Consortium   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Department of Radiation Oncology ^*  (United States)

Author keywords

Brainstem glioma; Farnesyltransferase inhibitors; Pediatric

Indexed keywords

PREDNISONE; TIPIFARNIB;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; BRAIN STEM; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; HUMAN; HYPOKALEMIA; HYPOXIA; INFECTION; KLUVER BUCY SYNDROME; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PETECHIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR GROWTH;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; QUINOLONES; RADIOTHERAPY;

EID: 60849101824     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-004     Document Type: Article

References (29)

1. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998;40:265-271.
2. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol. 2006;24:1266-1272.
3. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and over-expressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9:3620-3624.
4. Prendergast GC. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol. 2000;12:166-173.
5. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines. Cancer Res. 1995; 55:5302-5309.
6. Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery. 1998;43:124-131.
7. Pollack IF, Bredel M, Erff M. Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors. Pediatr Neurosurg. 1998;29:228-244.
8. Feldkamp MM, Lau N, Roncari L, Guha A. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 2001;61:4425-4431.
9. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Onco-gene. 1999;18:7514-7526.
10. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995;55:5310-5314.
11. Lebowitz PF, Du W, Prendergast GC. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J Biol Chem. 1997;272:16093-16095.
12. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farne syltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 1999;19:1831-1840.
13. Liu A, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltrans-ferase inhibitors. Mol Cell Biol. 2000;20:6105-6113.
14. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 1998;17:1439-1445.
15. Delmas C, Heliez C, Cohen-Jonathan E, et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer. 2002;100:43-48.
16. Jones HA, Hahn SM, Bernhard E, McKenna WG. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001;11:328-337.
17. 14C-labeled (R)-6-[amino(4-chlorophenyl) (1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos. 2002;30: 823-830.
18. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18:927-941.
19. Cloughesy TF, Kuhn J, Robins HI, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005;23:6647-6656.
20. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltrans-ferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
21. Gibbs JB, Pompliano DL, Mosser SD, et al. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem. 1993;268:7617-7620.
22. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A. 1992;89: 6403-6407.
23. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapep-tides. Cell. 1990;62:81-88.
24. Rowinsky EK. Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J Clin Oncol. 2006;24: 2981-2984.
25. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of hu man malignant astrocytomas is depen dent on Ras activation. Oncogene. 1997;15:2755-2765.
26. Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II-preclinical studies in a nude mouse model. Neurosurgery. 1999;45:1208-1214.
27. Bernhard EJ, Kao G, Cox AD, et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-rastransformed rat embryo fibroblasts. Cancer Res. 1996;56:1727-1730.
28. Bernhard EJ, McKenna WG, Hamilton AD, et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 1998;58:1754-1761.
29. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-in ducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24:3651-3656.